Back

The impact of peptide receptor radionucleotide therapy with Lutetium-177 DOTATATE on cardiac metastases in neuroendocrine tumors

1 September 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: treatments and outcomes Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Associate Professor Chadi Ayoub

Mayo Clinic Hospital, Phoenix (United States of America)

9 More presentations in this session

Presentation thumbnail
The predictive value of coronary artery calcium deposit for cardiovascular events in patients treated with immune checkpoint inhibitor therapy
Doctor M. Slieman (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Long term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis
Doctor J. Wong (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Assessment of right ventricular dysfunction in breast cancer patients undergoing anthracycline and trastuzumab treatment
Doctor M. Santa Ana Bayona (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Incidence of acute cardiovascular hospitalizations and association with hemodynamic biomarkers in cancer patients treated with Immune Checkpoint Inhibitor therapy
Doctor C. Mann (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Association between PCSK9 inhibitor with cause-specific morality amongst cancer survivors
Professor T. Liu (Tianjin, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: treatments and outcomes

The Event

Event poster

ESC Congress 2024

1 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Clinical and echocardiographic characteristics of neuroendocrine tumours and carcinoid heart disease: insights from a contemporary canadian cohort study
thumbnail
Congress Presentation
A case of carcinoid syndrome due to neuroendocrine tumor with multiple complications
thumbnail
Congress Presentation
Carcinoid heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources